% | $
Quotes you view appear here for quick access.

P L C SYSTEMS AŞ Message Board

  • investora2z investora2z May 4, 2013 8:23 AM Flag

    First European Patent for RenalGuard

    PLC System got its first patent for its product RenalGuard from the European Patent Office. The patent covers the core RenalGuard device, and its redundant infusion rate monitoring which allows RenalGuard to safely infuse saline at very high and accurate rates. The patent has a term extending to April 2027. The management was obviously happy about the development and marked it as a significant milestone. This patent will protect the company from infringement of its core technology in Europe. Europe is the biggest market for commercial sales of RenalGuard, and hence it was important for the company to strengthen its patent rights related to the product in the region. RenalGuard is the main product for the company. It had sold its other product, heart laser, two years ago to concentrate solely on RenalGuard therapy. The therapy is designed to rapidly remove contrast dyes that are potentially toxic to patients with impaired kidney function. The company continues to pursue additional patent in other countries like Japan and US. The company already has 8 US patents, one Canadian patent and one Japanese patent. The investigator-sponsored clinical trials of RenalGuard have given good results in Europe, and the company is making efforts to accelerate expanded distribution of RenalGuard around the world. Patent monetization / licensing is big business now with several smaller companies taking on big companies for enforcement of their patent rights. Once that stage comes for PLC Systems, it will be a real game changer for the investors. A report on Zacks in March had given a price target of $0.35 for the stock. The recent funding at a price much higher than the current market price indicates the faith of big investors. However, the future is dependent on the progress in the trials in US, and the management's ability to deliver on its promises.

    SortNewest  |  Oldest  |  Most Replied Expand all replies